In-Vitro Toxicology Testing Market (By Technology: Cell Culture Technology, High Throughput Technology, Molecular Imaging, OMICS Technology; By Application: Systemic Toxicology, Dermal Toxicity, Endocrine Disruption, Occular Toxicity, Others; By Method: Cellular Assay, Biochemical Assay, In-silico, Ex-vivo; End-user) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
The global in-vitro toxicology testing market size reached USD 30.72 billion in 2022 and it is projected to be worth around USD 90.42 billion by 2032, poised to grow at a CAGR of 11.4% during the forecast period from 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
An in vitro test is conducted outside of a living organism. This study involves the use of isolated cells, tissues, or organs. In vitro generally means “in glass”, and it refers to methods that are conducted on living material or components of living material cultured in test tubes or Petri dishes under particular conditions. In-vitro assays offer toxicity information in a less expensive as well as time-saving manner.
In vitro methods for the assessment of toxicity are one of the alternatives to whole-animal testing procedures. In vitro toxicology tests are rapidly gaining popularity in the regulatory community as they can lessen the number of animals used while providing predictions for some toxicological endpoints. In vitro, toxicology screening methods are the major tools to reduce the attrition of novel drug candidates as they progress through the development and discovery process.
In vitro toxicity, assays are employed to identify the potential of a new agrochemical, pharmaceutical, food additive, or any other chemical product to be dangerous to humans. In vitro studies are performed on mammalian cells or cultured bacteria and can be used as a screening to avoid the unnecessary use of animals in determining which candidates should go ahead for further safety testing.
In-vitro toxicology tests are widely used to replace multiple studies that earlier have been performed or tested on animals. The development of physiology-relevant in vitro models has recently advanced, and this is promising for enhancing the translation of test results to predict negative consequences in humans. Chemical toxicity testing is shifting toward a human cell and organoid-based in vitro method for several reasons such as ethical rightfulness, scientific relevancy, cost-effectiveness, and efficiency. In vitro toxicity tests adopt the latest advancement in vitro toxicology to assist clients in identifying compound viability in the preclinical phase of new product discovery or drug development. In vitro, toxicology studies can assist in reducing liabilities linked with the failure of late stage in the drug discovery process.
The global in-vitro toxicology testing market is expected to grow significantly due to the rising demand for drug discovery. To identify the toxic ability of compounds early in the drug discovery process, several specialist scientific expertise is needed with tailored solutions in order to address specific toxicological liabilities. The high cost of animal testing to measure toxicity, coupled with the social & ethical concerns for these conventional tests, is expected to drive the growth of the global in-vitro toxicology testing market.
The growth of the global in-vitro toxicology testing market is driven by the developments in toxicology research, such as the use of 3D in-vitro models, increasing government initiatives, increasing awareness regarding drug product safety, alternatives to the use of animals in pre-clinical research, rising advancements in-vitro toxicology assays, increasing demand for in-vitro assays and toxicology testing along with the developments in these assays to measure the safety of diagnostics, drugs, cosmetics, and others. In addition, the primary reason for accelerating the growth of the market is to minimize the last-stage drug failure risk by in-vitro toxicology assays.
Report Coverage | Details |
Market Size in 2023 | USD 34.22 Billion |
Market Size by 2032 | USD 90.42 Billion |
Growth Rate from 2023 to 2032 | CAGR of 11.4% |
Largest Market | North America |
Base Year | 2022 |
Forecast Period | 2023 To 2032 |
Segments Covered | By Technology, By Application, By Method, and By End-user |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver:
Increasing Governments and organizational support to avoid animal testing
The rising favorable government initiatives, which are highly concerned with banning animal testing and can lead to an increase in the adoption of in-vitro toxicology testing during the forecast period. Increasing investment by public and private agencies for the development of in-vitro test techniques. Funding programs are generally aimed to safeguard animal health, human health, and the environment by minimizing the dependency on animal models for the safe measurement of new chemical formulations and compounds.
Moreover, the increasing demand for cost-effective and safer alternatives to animal testing in the cosmetics, food, and pharmaceutical sectors acts as a primary fueling market revenue growth. The adoption of in-vitro toxicology testing is rapidly gaining immense popularity as these days people are becoming more aware and concerned about the adverse consequences of chemicals on both the environment and human health.
Restraints:
Lack of skilled professionals
The lack of skilled professionals is projected to hamper the global in-vitro toxicology testing market's growth. There is a requirement for skilled professionals to perform various activities such as experiments, analyzing data, and making observations. In addition, the less capability of in-vitro models to determine autoimmunity and immunostimulant is likely to limit the expansion of the global in-vitro toxicology testing market during the forecast period.
Opportunities:
Technological advancement
The continuous advancements in technology, especially in the healthcare sector, are observed to offer a lucrative opportunity for the market’s growth during the forecast period. The rising penetration/deployment of technologies such as 3D cell culture models and high-throughput screening are observed to promote the market’s growth, which encourage the adoption of in-vitro toxicity testing services. Advanced technologies promise to help experts to develop more relevant and precise data on the toxicity of chemicals and reduce the dependency on animal testing.
Additionally, the automation of multiple systems is another advancement in the market to offer opportunities during the forecast period. The automation of systems allows proper data analysis. Technological advancements allow cost-effective and time-saving procedures for the manufacturers by boosting the speed of drug testing.
On the basis of type, the global in-vitro toxicology testing market is segmented into systemic toxicology, dermal toxicity, endocrine disruption, ocular toxicity, and others. The systemic toxicology segment is expected to expand at a robust growth rate during the forecast period due to a comprehension of negative reactions that occur in a shorter time period after drug administration. Toxic effects may occur at several sites. It plays a crucial role in risk assessment during the drug development process. There are many types of systemic toxicology studies such as genetic Toxicity, developmental Toxicity, sub-acute systemic toxicity, acute systemic toxicity, chronic systemic toxicity, and sub-chronic systemic toxicity. On the other hand, the dermal toxicity segment is projected to grow at a significant rate. In-vitro toxicology assays for evaluating dermal toxicity are cost-reliable, simple, and highly effective rather than animal testing.
Based on the Technology, the global in-vitro toxicology testing market is segmented into Cell Culture Technology, High Throughput Technology, Molecular Imaging, and OMICS Technology. The cell culture technology segment is expected to dominate the market over the forecast period. Advancements in human cell culture exposure enabled the development of in-vitro assay systems, which are demonstrative, highly predictive, and well-suited for toxicity screening of a wide range of chemicals. In-vitro toxicology includes using tissues or cells grown and maintained in an artificially controlled environment, outside of the natural environment to test the toxic attributes of several mixtures and compounds.
Based on the Method, the global in-vitro toxicology testing market is segmented into cellular assay, biochemical assay, in-silico, and ex-vivo. The cellular assay segment is expected to hold a key account share during the forecast period. Cellular assays can be used to efficiently assess the cytotoxicity, biochemical mechanisms, off-target interactions, and biological activity in biomedical research as well as drug-discovery screening applications. Cellular assays are attributed to the high revenue in the in-vitro toxicology testing market. Cellular assays as in-vitro models provide various advantages including minimum cost, speed of analysis, and technological advancement such as automation. Moreover, several efforts by key market players for the development of novel cellular assays are expected to boost market growth. On the other hand, the In-silico segment is projected to grow at a significant CAGR during the forecast period.
Based on the end user, the global in-vitro toxicology testing market is segmented into the pharmaceutical industry, cosmetics & household products, academic institutes & research laboratories, diagnostics, chemicals industry, and food industry. The pharmaceutical industry segment is expected to capture a significant market share over the forecast period due to the increasing adoption of toxicology testing for analyzing the pharmacokinetic attributes of pharmaceutical drugs. Generic drugs have enormous demand of assays for toxicology testing. The ongoing research and development for new drugs and a candidate drug pipeline are expected to spur the demand for in-vitro testing methods. Cytotoxicity is used for pharmaceutical drug testing by screening technology prior to the use of any other toxicology testing. For quality control testing of manufactured drugs, Cytotoxicity testing is used.
On the other hand, the diagnostics segment is expected to expand at a robust growth rate in the coming years owing to the increase in the number of diagnostic devices. In addition, key market players are offering a comprehensive diagnostics product line for the detection of therapeutic drug monitoring as well as point-of-care drug testing.
North America holds the largest share of the market. The region is expected to sustain its dominance during the forecast period owing to the sophisticated healthcare infrastructure, supportive government regulations, the increasing presence of prominent market players, advanced infrastructure & shifting focus on drug discovery in the region. Technological advancements and increasing adoption of in-vitro testing methods in the region also act as drivers for the growth of in-vitro toxicology testing market. The launch of biologics by biopharmaceutical players in the United States has resulted in the rapid adoption of toxicology testing. The expansion of laboratory capabilities in the region has enabled clients to build toxicological profiles of biopharmaceuticals, medical devices, chemicals, and cosmetics.
On the other hand, the Asia Pacific market is growing at a significant CAGR during the forecast period. The rapid growth of the market in the region is owing to the rapidly increasing geriatric population in need of medicines, several government incentives for enhancing technology and development, rising healthcare expenditure, and rising focus of government organizations to encourage toxicology testing by in-vitro methods. The conducting of clinical trials in the region is relatively cost-effective.
Segments Covered in the Report:
By Technology
By Application
By Method
By End-user
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on In-Vitro Toxicology Testing Market
5.1. COVID-19 Landscape: In-Vitro Toxicology Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global In-Vitro Toxicology Testing Market, By Technology
8.1. In-Vitro Toxicology Testing Market, by Technology, 2023-2032
8.1.1. Cell Culture Technology
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. High Throughput Technology
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Molecular Imaging
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. OMICS Technology
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global In-Vitro Toxicology Testing Market, By Application
9.1. In-Vitro Toxicology Testing Market, by Application, 2023-2032
9.1.1. Systemic Toxicology
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Dermal Toxicity
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Endocrine Disruption
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Occular Toxicity
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global In-Vitro Toxicology Testing Market, By Method
10.1. In-Vitro Toxicology Testing Market, by Method, 2023-2032
10.1.1. Cellular Assay
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Biochemical Assay
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. In-silico
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Ex-vivo
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global In-Vitro Toxicology Testing Market, By End-user
11.1. In-Vitro Toxicology Testing Market, by End-user, 2023-2032
11.1.1. Pharmaceutical Industry
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Cosmetics & Household Products
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Academic Institutes & Research Laboratories
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Diagnostics
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Chemicals Industry
11.1.5.1. Market Revenue and Forecast (2020-2032)
11.1.6. Food Industry
11.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global In-Vitro Toxicology Testing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Technology (2020-2032)
12.1.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.3. Market Revenue and Forecast, by Method (2020-2032)
12.1.4. Market Revenue and Forecast, by End-user (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Method (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Method (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End-user (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.3. Market Revenue and Forecast, by Method (2020-2032)
12.2.4. Market Revenue and Forecast, by End-user (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Method (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Method (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End-user (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Method (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End-user (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Method (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End-user (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.3. Market Revenue and Forecast, by Method (2020-2032)
12.3.4. Market Revenue and Forecast, by End-user (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Method (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Method (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End-user (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Method (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End-user (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Method (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End-user (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.3. Market Revenue and Forecast, by Method (2020-2032)
12.4.4. Market Revenue and Forecast, by End-user (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Method (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Method (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End-user (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Method (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End-user (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Method (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End-user (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.3. Market Revenue and Forecast, by Method (2020-2032)
12.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Method (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Method (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End-user (2020-2032)
Chapter 13. Company Profiles
13.1. Charles River Laboratories International, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. SGS S.A.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck KGaA
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Eurofins Scientific
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Abbott Laboratories
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Laboratory Corporation of America Holdings
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Evotec S.E.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Thermo Fisher Scientific, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Quest Diagnostics Incorporated
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Agilent Technolgies, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client